Side effects of retroviral gene transfer into hematopoietic stem cells.

  title={Side effects of retroviral gene transfer into hematopoietic stem cells.},
  author={Christopher Baum and Jochen D{\"u}llmann and Zhixiong Li and Boris Fehse and Johann Meyer and David A. Williams and Christof von Kalle},
  volume={101 6},
Recent conceptual and technical improvements have resulted in clinically meaningful levels of gene transfer into repopulating hematopoietic stem cells. At the same time, evidence is accumulating that gene therapy may induce several kinds of unexpected side effects, based on preclinical and clinical data. To assess the therapeutic potential of genetic interventions in hematopoietic cells, it will be important to derive a classification of side effects, to obtain insights into their underlying… 

Figures and Tables from this paper

Gene therapy for inherited disorders of haematopoietic cells.

  • C. KleinC. Baum
  • Biology, Medicine
    The hematology journal : the official journal of the European Haematology Association
  • 2004
Improved retroviral or lentiviral techniques allow stable gene transfer in >10% of repopulating cells cultured in vitro, but severe impediments are still encountered with respect to achieving sufficient and long-lasting transgene expression levels and appropriate numbers of transgenic cells in vivo.


The subsequent reporting of severe adverse events in clinical trials casted doubts on the predictive value of conventional pre-clinical testing, and encouraged the development of new assays for assessing the relative genotoxicity of various vector designs.

Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects

It is argued that episomally maintained self-replicating vectors combined with physical methods of delivery show the greatest promise among nonviral gene transfer strategies for the treatment of disorders of the hematopoietic system.

Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

The subsequent reporting of severe adverse events in clinical trials cast doubts on the predictive value of conventional preclinical testing, and encouraged the development of new assays for assessing the relative genotoxicity of various vector designs.

Contributions of gene marking to cell and gene therapies.

Marking studies in humans, murine xenografts, and large animals have helped optimize conditions for gene transfer into CD34(+) hematopoietic progenitors, contributing to the achievement of gene transfer efficiencies sufficient for clinical benefit in several serious genetic diseases.

Retroviral Vectors: Post Entry Events and Genomic Alterations

Recent insights gained on the mechanisms of insertional mutagenesis based on intrinsic target site selection of different retrovirus families are summarized and examples of side effects occurring in ongoing human gene therapy trials are discussed.

[Development and application of gene therapy technologies].

To cope with this serious problem, basic studies are required to improve the safety of retroviral vectors and to develop the method for site-specific integration of transgenes, in order to obtain therapeutic efficacy of hematopoietic stem cell gene therapy in many other disorders.

Gene Therapy Targeting Hematopoietic Cells: Better Not Leave It to Chance

Gene therapy targeting hematopoietic cells has arrived at a new stage of potency and the first serious adverse events related to random insertion of foreign DNA into cellular chromosomes are confronted.

A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation.




Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells.

More recent findings from nonhuman primate investigations focusing on hematopoietic stem cells or lymphocytes as target populations are summarized, and specific preclinical issues are highlighted, including safety.

Gene Therapy 2000.

The use of gene transfer methods to genetically manipulate hematopoietic stem cell targets, recent advances in technology that are addressing problems that have prevented widespread successful translation, and recent regulatory issues related to human gene therapy trials are reviewed.

Progress in the use of gene transfer methods to treat genetic blood diseases.

A report by French physician-scientists suggests a successful application of gene transfer methods in the treatment of two children with severe combined immunodeficiency (SCID) due to defective

Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells

Pre-clinical studies indicate that efficient retrovirus-mediated gene transfer into hematopoietic stem cells and progenitor cells can be achieved by co-localizing retroviral particles and target

Genetic marking as an approach to studying in vivo hematopoiesis: progress in the non-human primate model

Autologous transplantation studies in non-human primates have just begun and have the potential to shed light on controversial issues such as the number of clones contributing to stable hematopoiesis, clonal succession, and lineage commitment, as well as the effect of clinically relevant manipulations such as cytokines, chemotherapy, and radiation on hematopoliesis.

Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells.

These studies indicate that retroviral vectors which employ viral LTRs for the expression of inserted sequences make it possible to obtain high levels of a desired gene product in most hematopoietic cell lineages for close to the lifetime of bone marrow transplant recipients.

Animal xenograft models for evaluation of gene transfer into human hematopoietic stem cells.

The current review will discuss the murine xenograft models that have been used recently to determine optimized methods for gene transfer into normal human hematopoietic stem cells.

Retroviral vector-mediated gene expression in hematopoietic cells.

The rationale underlying the further improvement of such cis-elements of the vector is reviewed here and the overall level, clonal variability, response to differentiation and persistence of transgene expression in vivo are reviewed.

In vivo persistence of retrovirally transduced murine long-term repopulating cells is not limited by expression of foreign gene products in the fully or minimally myeloablated setting.

It is concluded that even with very low dose conditioning, engraftment by genetically modified LTRC cells at clinically significant levels can be achieved without evidence for clearance of cells known to be expressing immunogenic proteins.

Human cord blood cells as targets for gene transfer: potential use in genetic therapies of severe combined immunodeficiency disease

It is demonstrated that CB progenitor and stem cells can be efficiently infected using retroviral vectors and suggest that CB cells may provide a suitable target population in gene transfer protocols for some genetic diseases.